SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Ryvu Therapeutics to Present Phase II Clinical Data at ASH 2026

Ryvu Therapeutics will present first clinical data from the Phase II JASPIS-01 study of dapolsertib and preliminary efficacy data from the RIVER-81 expansion cohort of romaciclib with venetoclax at ASH 2026.

SquawkNews Desk

Related stories

Google invertirá USD 15.000 millones en Malasia La inversión prevista contempla centros de datos, energía y agua. M impact | EQUITY | Nov 04, 2026, 03:34 PM UTC General Motors shares hit record high, up 4% M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC SolarEdge Reports Q3 Revenue of $326.1 Million, Adjusted EPS of $0.29 Third-quarter revenue was $326.1 million, in line with the midpoint of prior guidance. Adjusted EPS was $0.29 versus FactSet consensus of $0.04. SolarEdge forecast fourth-quarter r M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC Kempower Reports Q3 Revenue Decline and Lowers 2026 Guidance Kempower reported a 10% revenue decline and negative operative EBIT in Q3 2026, citing weakening charging investment. It lowered full-year 2026 guidance, while reporting a €128 mil M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC Skue Sparebank Reports Q3 Pretax Profit of NOK 102.5 Million M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC Microsoft Shares Hit Record High, Up 6.1% M impact | EQUITY | Nov 04, 2026, 03:32 PM UTC